HilleVax, Inc (HLVX) Gets a Buy Rating from SVB Securities

In a report issued on July 20, David Risinger from SVB Securities maintained a Buy rating on HilleVax, Inc (HLVXResearch Report). The company’s shares closed last Thursday at $12.36.

According to, Risinger is a 3-star analyst with an average return of 3.7% and a 58.8% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Prometheus Biosciences, and Horizon Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for HilleVax, Inc with a $32.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Read More on HLVX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More